Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069940 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00069940: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT00069940 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00069940, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given together with sargramostim in treating patients with advanced sarcoma or brain tumor.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL telomerase: 540-548 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
What the finished NCT00069940 record still lists
NCT00069940 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT00069940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00069940 about?
NCT00069940 is a clinical study titled "Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill ...
What is the current status of trial NCT00069940?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00069940?
The interventions under investigation include: sargramostim (BIOLOGICAL), telomerase: 540-548 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00069940?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia